Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus whole-brain radiotherapy versus placebo plus whole-brain radiotherapy in SCLC brain metastases (Phase III)
ChiCTR2500108747Phase 3Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing ACT001 + whole-brain radiotherapy with Placebo + whole-brain radiotherapy (2 arms). Primary endpoint: Overall survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500108747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108747.